Schering Corporation

Enzon, Inc.

Charles W McNemar

Paul Reichert

Alan W Hruza

William T Windsor

M Arshad Siddiqui

Gerald Wayne Shipps, Jr

Yongqi Deng

Lianyun Zhao

Rumin Zhang

Patrick J Curran

Stephen Tindall

David Parry

Todd W Mayhood

Emma M Lees

Ashit K Ganguly

Vincent Stewart Madison

Janeta Popovici-Muller

Tattanahalli L Nagabhushan

Thierry Olivier Fischmann

Patricia C Weber

Jose S Duca

Nagamani Nagabhushan

Eric William Kaler

Tattanahalli L Nagahhushan

Nagamani Nagahhushan

Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

High affinity quinoline-based kinase ligands

Inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

High affinity thiophene-based and furan-based kinase ligands

This invention relates to pharmaceutical composition comprising a lipophilic oligosaccharide antibiotic in a substantially monomeric form.

Monomeric lipophilic oligosaccharide antibiotic compositions

Substantially pure histidine-linked protein-polymer conjugates and processes for their preparation are disclosed. The processes include contacting a protein with an activated polymer under conditions sufficient to facilitate covalent attachment of at least a portion of the polymer strands on histidine residues of the protein and thereafter substantially separating the histidine-linked conjugates from the remaining reactants.

Substantially pure histidine-linked protein polymer conjugates

A method for producing a crystalline zinc interferon (IFN) .alpha.-2 comprising forming a soluble solution of IFN .alpha.-2 and a metal acetate salt under condtions wherein supersaturation and metal alpha interferon crystals occur.

Method for producing metal-interferon-.alpha. crystals

The present invention provides for crystalline zinc-interferon alfa-2 (IFN .alpha.-2) having a monoclinic morphology. The present invention further provides for crystalline cobalt-IFN .alpha.-2, crystalline calcium-IFN .alpha.-2, and crystalline IFN .alpha.-2 having a serum half-life of at least about 12 hours when injected into a primate. The present invention further provides for a method for producing a crystalline IFN .alpha.-2 comprising forming a soluble metal-IFN .alpha.-2 complex, and equilibrating the soluble metal-IFN .alpha.-2 complex in solution with an acetate salt of the metal under conditions that will cause the metal-IFN .alpha.-2 solution to become supersaturated and form crystalline metal-IFN .alpha.-2. The present invention also includes crystalline metal-alfa interferon having monoclinic, plate and needle morphologies.

Metal-interferon-alpha crystals

Growing community of inventors

High Bridge, NJ, United States of America

Charles W McNemar